Dotmatics uses cookies for analytics, advertising, and user experience purposes. You can read more about how we use cookies and how they can be controlled in our privacy policy. By continuing to use this site, you consent to the use of cookies.

Webinar | Decoding Antibody Discovery — The Future of Next-Gen Biologics

Register Now
Dec 13, 2022
8:00am PDT
11:00am EST
17:00 CET
Online

Webinar | Decoding Antibody Discovery — The Future of Next-Gen Biologics

Antibodies have established themselves as one of the most important classes within the biologics space, and developing these therapeutics requires a series of successful decisions throughout the early-discovery process. Antibody discovery is a complex and often circuitous route, which, if not efficiently optimized, can cost investigators valuable time and money. In this GEN webinar, our subject matter experts, Christian Olsen and Dr. Nimesh Joseph, will provide an overview of current trends in monoclonal antibody research and discovery and how science and technology are converging to create cutting-edge workflows designed to drive innovation and breakthroughs in the largest biologics therapeutic class today

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Register Now

Speakers and Panelists

Christian Olsen

Christian is a renowned bioinformatics scientist with deep expertise in infectious disease and public health, drug target selection, and drug resistance surveillance. As the product management lead, Christian guides strategy and development for antibody discovery workflows within the Dotmatics Biology solution to radically improve the way scientists work.

Nimesh Joseph

Nimesh is a trained cell and molecular biologist with over 20 years of research experience, primarily engaged in target validation studies across both academia and biotech. In his current role as a Senior Solution Engineer at Dotmatics, Nimesh is a trusted advisor that oversees solution design at the leading pharmaceutical and biotech research teams.